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PubChem Summary Bioassay Identifier (AID): 1772
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Chemical IUPAC Name: 4-[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2yl]benzenesulfonamide [ML 141]
Probe Structure & Characteristics:
Molecular Weight
407.48544 [g/mol]
Molecular Formula
C22H21N3O3S
XLogP3-AA
3.6
H-Bond Donor
1
H-Bond Acceptor
6
Rotatable Bond Count
5
Exact Mass
407.130362
MonoIsotopic Mass
407.130362
Topological Polar Surface Area
85
Heavy Atom Count
29
Formal Charge
0
Complexity
668
Isotope Atom Count
0
Defined Atom StereoCenter Count 0
Undefined Atom StereoCenter Count 1
Defined Bond StereoCenter Count 0
Undefined Bond StereoCenter Count 0
Covalently-Bonded Unit Count
1
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ML 141

Table 1. Profile of the Chemical Probe CID2950007 on Ras-Related GTPases
CID/
ML#**

Target
Name‡

2950007/
141

Nucleotidedepleted
Cdc42 wild
type with 1
nM GTP and 1
mM Mg2+
Cdc42 wild
type

IC50/EC50
(µM)

Anti-target
Name(s)‡

IC50/EC50
(μM)

Selectivity
*

Assay Name and/or AIDs

0.2

Glutathione S
–transferase

n.d

n.d.

AID 2376

2.6

Glutathione S
–transferase

>100

>50

5.4

Glutathione S
–transferase

>100

>50

2950007/
141

Cdc42
activated
mutant
Ras
wild type

>100

Glutathione S
–transferase

>100

Not relevant

AID 1758, 1762, 761, 1333,
1334, 1772, 2009, 2019, 2020,
2021, 2022, 2037, 2372, 2373,
2374, 2375, 2376, 2378, 2418
AID 1758, 1762, 761, 1333,
1334, 1772S, 2009, 2019, 2020,
2021, 2022, 2037
AID 759, 1759, 1761, 1335,
2038, 2047, 2053, 1772

2950007/
141

Ras activated
mutant

>100

Glutathione S
–transferase

>100

Not relevant

AID 1341

2950007/
141
2950007/
141

Rab 7
wild type
Rab 2a wild
type

>100

Glutathione S
–transferase
Glutathione S
–transferase

>100

Not relevant

>100

Not relevant

AID 758, 1760, 1336, 2031,
204, 1772
AID 1763, 760, 1337, 2033,
2045, 2046, 1772

2950007/
141

>100

Glutathione S
–transferase

>100

Not relevant

AID 764, 1339, 2039, 2048,
2051, 1772

2950007/
141

Rac1
activated
mutant
Rac 1 wild
type

>100

Glutathione S
–transferase

>100

Not relevant

AID 757, 1769, 1340,1772,
2027, 2040, 2055, 1772

2950007/
141

Cdc42 wild
type

2

n.d.

n.d.

n.d.

2950007/
141

Cdc42 wild
type

< 10

n.d.

n.d.

n.d.

2950007/
141
2950007/
141

Cdc42 wild
type
Nucleotidedepleted
Cdc42 wild
type
Cdc42-PAKPBD complex
Cdc42

< 10

n.d.

n.d.

n.d.

< 10

n.d.

n.d.

n.d.

primary assay with 1 mM
Mg2+
AID 2393
GTP binding with 1 mM
EDTA
AID 2378
GTP binding with Mg2+
AID 2373
GTP binding with Mg2+ AID
2372

< 10

n.d.

n.d.

n.d.

< 10

n.d.

n.d.

n.d.

2950007/
141

Rac1

> 10

n.d.

n.d.

n.d.

2950007/
141

Cdc42

n.d.

n.d.

n.d.

2950007/
141
2950007/
141

2950007/
141
2950007/
141

>100

< 10

Pull down assay
2374
Active cdc42 GLISA in 3T3
cells + EGF
AID 2375
Active Rac1 GLISA in 3T3
cells s+ EGF
AID 2375
Filopodia formation in 3T3
cells + bradykinin
AID 2418

Recommendations for the scientific use of this probe and prior art overview:
2

The probe is a potent, selective and reversible non-competitive inhibitor of Cdc42 GTPase
suitable for in vitro assays. In the most relevant secondary biochemical assay using
nucleotide-depleted wild type Cdc42 in the presence of Mg2+ and 1 nM GTP (AID 2376),
CID2950007 had an IC50 ~ 200 nM, an acceptable probe potency within MLPCN guidelines.
In the primary HTS bead-based assay using 1 mM EDTA and 100 nM BODIPY-FL-GTP,
potency for CID2950007 was IC50 = 2.6 and 5.4 µM for Cdc42 wild type and activated
mutant, respectively. No appreciable inhibitory activity up to 100 µM was observed with
Rac1, Rab2, Rab7 or Ras in the multiplex screen. The Cdc42-selective probe has low (1-10)
micromolar activity in qualitative and semi-quantitative cell-based assays such as GLISA
assay for active GTP-bound Cdc42/PAK-PBD complex and Cdc42-dependent function in
filopodia formation in 3T3 cells. The probe appears broadly specific since it has been tested
in 263 MLPCN assays with only 1 confirmed IC50 (2.8 µM) in a T. cruzi parasite replication
assay in 3T3 cells that is likely Cdc42-dependent (AID 2044). As stated in the CPDP for this
project there was no prior art describing direct Cdc42 inhibitors, so the discoveries reported
here are highly innovative and impactful.
The function of the Rho family GTPases (Rac, Rho, and Cdc42) are known to be highly
complementary if not overlapping. These include roles in cell adhesion, cytoskeletal
arrangement, phagocytosis and host-pathogen interactions, motility and migration,
membrane protein traffic, etc. These functions are likely to be usefully measured in human
leukocytes such as neutrophils and selected leukocyte cell lines. Cdc42 selective inhibitors
such as those reported here should help untangle the roles of the proteins in this family.
This has proven difficult with protein knockdowns because of the potential compensation in
expression of other family members. For these reasons, the identification of secramine, a
molecule that inhibits membrane traffic out of the Golgi apparatus was viewed as a
breakthrough. The indirect and non-selective Cdc42 inhibitor secramine was synthesized
predicated on brefeldin A, which is a fungal metabolite. Secramijne was reported to work by
inhibiting “activation of the Rho GTPase Cdc42, a protein involved in membrane traffic, by a
mechanism dependent upon the guanine dissociation inhibitor RhoGDI. RhoGDI binds Cdc42
and antagonizes its membrane association, nucleotide exchange and effector binding. In
vitro, secramine inhibits Cdc42 binding to membranes, GTP and effectors in a RhoGDIdependent manner. In cells, secramine mimics the effects of dominant-negative Cdc42
expression on protein export from the Golgi and on Golgi polarization in migrating cells.
RhoGDI-dependent Cdc42 inhibition by secramine illustrates a new way to inhibit Rho
GTPases with small molecules and provides a new means to study Cdc42, RhoGDI and the
cellular processes they mediate” (Pelish, 2006)
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1. Scientific Rationale for Project
Rho-family GTPases and their effector proteins are major regulators of signaling pathways
that control diverse biological processes. The most extensively characterized Rho-family
members are RhoA, Rac1 and Cdc42 (Bishop, 2000). Actin cytoskeleton reorganization is a
well characterized function for Rho GTPases: Rac1, Cdc42 and RhoA regulate lamellipodia,
filopodia and stress fiber formation, respectively (Bishop, 2000). Rho-family GTPases also
regulate cell-cycle progression, cell growth and survival, gene transcription, adhesion,
migration, phagocytosis and cytokinesis as well as neurite extension and retraction, cellular
morphogenesis and polarization (Chimini, 2000; Etienne-Manneville, 2002; Raftopoulou,
2004). Rho GTPases function as molecular switches by cycling between inactive/GDP-bound
and active/GTP-bound states (Jaffe, 2005). Cycling between these states is controlled by
cellular proteins such as GDP-dissociation-inhibitors (GDI), guanine nucleotide exchange
factors (GEFs) and GTPase-activating proteins (GAP). Rho GTPases exist in cells
predominantly in the inactive GDP-bound form associated with GDIs. By binding to the Cterminal tail of GTPases, GDIs prevent GTPases from binding to the plasma membranes and
keep GTPases in the cytoplasm (Johnson, 2009; Ridley, 2006). GEFs promote GDP
exchange with GTP and activate GTPases whereas GAPs stimulate GTP hydrolysis to GDP,
thus inactivating GTPases (Rossman, 2005; Bos, 2007).
The function of Rho-family GTPases in disease pathogenesis has been reviewed extensively
(Takai, 2001; Rossman, 2005; Van Hennik, 2005; Boettner, 2002; Gomez del Pulgar, 2005;
Sahai, 2002; Vega, 2008). Identifying small, cell permeable molecules that selectively and
reversibly regulate Rho GTPases is of high scientific and potentially therapeutic interest.
There has been limited success in identifying inhibitors that specifically interact with small
Rho family GTPases. Recently a couple of low molecular weight inhibitors for Rac1 were
described (Gao, 2004; Shutes, 2007). NSC23766 is cell-permeable and directly binds to a
groove of Rac1 that is critical for GEF interaction. Therefore, NSC23766 blocks Rac
activation by some, but not other, GEFs that activate Rac1 (Gao, 2004). More promising is
the Rac-specific inhibitor EHT1864 which binds tightly to Rac1, Rac1b, Rac2 and Rac3,
reducing their affinity for GTP. EHT1864 induces nucleotide release and inhibits nucleotide
rebinding. Because all Rac effector interactions are GTP-dependent, EHT1864 is expected to
block Rac1 interaction with all effectors (Shutes, 2007). The only known small molecule
inhibitor of Cdc42 activation, secramine, inhibits Cdc42 activation only in its prenylated
form. Activation of the non-prenylated form of the Cdc42, which does not bind GDI, was
unaffected by the inhibitor indicating that secramine inhibits activation of Cdc42 in a Rho
GDI-dependent manner. This was supported by the finding that secramine prevents
translocation of prenylated Cdc42 to membranes (Pelish, 2006).
Here we describe a bead-based multiplex flow cytometry HTS assay which allowed
simultaneous screening of six GTPase targets against ~200,000 compounds in the Molecular
Libraries Screening Center Network (MLSCN) library. A potent and selective, reversible noncompetitive Cdc42 inhibitor was discovered and SAR of structural analogs explored by
synthetic chemistry. The chemical probe and related analogs are biologically active in cell
based assays of Cdc42 activation (ELISA) and function (filopodia formation).

4

2. Project Description
The project goal was to identify selective inhibitory probes for modulating the GTP-binding
and activity of representative members of Rho, Ras and Rab GTPase families with > 10-fold
inhibitory selectivity and specific emphasis on Cdc42 vs Rac1. As summarized on page 1 and
in Tables 1-2, the profile of the chemical probe CID2950007 meets the objectives set out
below that were agreed to in the approved CPDP:


A probe should have IC50 < 10 µM for Cdc42, Rac1, Rab or Ras and be efficacious at >
50% inhibition in the multiplex in vitro binding assay (Screening Center).



A probe should have IC50 < 5 µM in the primary assay and efficacy of > 65% to advance
into secondary assays



Compounds demonstrating selectivity towards Cdc42 will be assessed in the appropriate
microscopy, cell-based assay, as outlined in the flow chart. Compounds having no
cytotoxic effects and having a IC50 of 10-50 µM will advance into the appropriate assay



Compounds with Cdc42 activity that meet the above requirements will progress into cell
based ELISA assay to determine target activity. Confirmation will result in a probe.



Probes resulting from this effort will be assessed with respect to their promiscuity on
other biological targets using a broad spectrum profiling panel. Also, the chemical
stability and solubility of the probe will be evaluated. These data will be the subject of a
post-probe enhancement, extended characterization effort.

a) Bioassays
i) Primary HTS and Dose Response Assays
The assays are described in detail in Schwartz et al., 2008 and Surviladze et al., 2010.
Individual GST-GTPases (H-Ras wt, Cdc42 wt, Rac1 wt and RacQ61L mutant were
purchased from Cytoskeleton and GST-Rab2, GST-Rab7 were purified as described by
Schwartz, 2008) were attached to 4 µm diameter glutathione-beads (GSH-beads)
distinguished by different intensities of red color (various magnitude of emission at 665 +/10 nm with excitation at 635 nm). Bead sets for multiplex assays were custom synthesized
by Duke Scientific Corp (Fremont, CA), but may now be ordered from Thermo/Fisher.
Individual GTPase-coupled beads were washed twice with 100 µl ice cold NP-HPS buffer
[(0.01% (vol/vol) NP-40, 30 mM HEPES pH 7.5, 100 mM KCl, 20 mM NaCl,] supplemented
with 1mM EDTA, 0.1% BSA and 1 mM DTT and were pooled together immediately prior to
loading of 5 µl of the mixture in each well of the assay plates. Next 0.1 µl of test
compounds (1 mM stock in DMSO) were added to individual wells to give a final
concentration of 10 µM compound and 1% DMSO, after which 5 µl BODIPY- FL-GTP (200 nM
stock in NP-HPSE) was added to each well. Positive controls, contained the bead mixture,
0.1 µl DMSO (1% final) and fluorescent GTP. Negative controls, contained the bead mixture
with fluorescent GTP, 0.5 mM unlabeled GTP as a competitor, and 1% DMSO. Plates were
incubated on rotator for 40-45 min at 4°C and sample analysis was conducted with a
HyperCyt high throughput flow cytometry platform as described previously (Kuckuck,
2001). Flow cytometric light scatter and fluorescence emission at 530 +/- 20 nm (FL1) and
665 +/- 10 nm (FL8) were collected on a Cyan ADP flow cytometer (Beckman Coulter,
Fullerton, CA). Resulting time-dependent data (one file per plate) were analyzed using
IDLQuery software to determine the compound activity in each well. Gating based on
forward scatter (FS) and side scatter (SS) parameters was used to identify singlet bead
populations. Gating based on FL8 emission distinguishes the beads coated with different
proteins, and the median fluorescence per bead population was calculated. A compound
5

was considered a “potential active” if the change in activity was greater then 20% from
baseline. Baselines were set to 100% based on measurements from the 1% DMSO
containing positive controls as further described in PubChem (PubChem #72). As published
(Surviladze et al., 2010), assay performance was robust for all the GTPases selected with
for example average Z' = 0.87 ± 0.04 for Cdc42, 0.85 ± 0.04 for Rac1 wt, and 0.90 ± 0.03
for Rac1Q61L activated mutant. Dose response measurements were also previously
described (Surviladze, 2010). Briefly, compounds were serially diluted 1:3 a total of eight
times from a starting concentration of 10 mM giving a 9-point dilution series in DMSO. The
final concentrations of inhibitors in the assay ranged from 10 nM to 100 µM. Dose–response
analyses were examined in the presence of NP-HPS buffer containing: a) 1mM EDTA; or b)
1mM MgCl2. For assays with EDTA we used one multiplex (Rab7 wt, Rab2 wt, H-Ras wt, HRasG12V, Cdc42 wt, and Cdc42Q61L) and 3 single-plexes (for Rac1 wt, Rac1Q61L and GSTGFP). In experiments including magnesium, six GST-GTPases were assayed simultaneously
in a single multiplex (Rac1 wt, Rac1Q61L, RhoA wt, RhoAQ63L, Cdc42 wt and Cdc42Q61L)
and 1 nM BODIPY-FL-GTP binding was measured in the presence or absence of the serial
drug dilution series. Each dose response series was run in duplicate.
Equilibrium binding assay: wild-type GST-Cdc42 (4 µM) was bound to GSH-beads overnight
at 4°C. Cdc42 on GSH-beads was depleted of nucleotide by incubating with 10 mM EDTA
containing buffer for 20 min at 30°C, washing twice with NP- HPS buffer, then re-suspended
in the same buffer containing 1 mM EDTA/or 1 mM MgCl2, 1 mM DTT and 0.1% BSA. Cdc42
unbound sites were blocked by incubation of protein–bead complex for 15 min at RT. Thirty
µl of this suspension incubated with 20 mM inhibitor for 3 min at RT and added 30 µl of
various concentrations of ice cold BODIPY-FL-GTP. Samples incubated at 4oC for 45 min and
binding of fluorescent nucleotide to enzyme measured using an Accuri flow cytometer. Raw
data were exported and plotted using GraphPad Prism software.
ii) Secondary Cell-Based Assays
In vitro Cdc42-GTPγS Complex Formation with PAK-PBD
The Rac/Cdc42 (p21) binding domain (PBD) of the human p21 activated kinase 1 (PAK)
specifically binds GTP- and not GDP-bound Cdc42. The PAK-PBD domain can be used to
specifically precipitate active, GTP-bound Cdc42. For analysis of the effect of
CID2950007/MLS000693334 on the formation of the complex between PAK-PBD and the
GTP-bound active form of Cdc42 in vitro, 40 nM His-Cdc42 wt was incubated for 20 min at
30C with various concentrations of GTPS in the presence of 1 mM EDTA containing NP-HPS
buffer. Reactions were stopped by adding excess MgCl2. The mixture was incubated with
15µl PAK-PBD beads (Cytoskeleton Inc., Denver, CO) for 1 h then washed 2 times and the
PAK-PBD-bead-associated active Cdc42 was analyzed by Western blot probed with a mAb
directed against Cdc42 (Cytoskeleton Inc., Denver, CO) and Mouse TrueBlot Ultra:
Horseradish Peroxidase anti-mouse IgG (eBioscience. San Diego, CA) followed by ECL
detection (Thermo Scientific, Rockford, IL).
G-LISA assays for Cdc42 and RAC1 in 3T3 cells
Swiss 3T3 cells were cultured and serum starved following standard procedures
(Cytoskeleton, Inc., Denver, CO). Individual cultures grown in 6-well dishes were incubated
with inhibitor for 1 h and subsequently stimulated for 2 min with 10 ng/mL EGF. Cells were
washed with ice-cold phosphate buffered saline (PBS) containing calcium and magnesium
and further processed for protein and G-LISA assays. Positive controls included Cdc42-GTP
or Rac1-GTP provided in the kit and cell lysate prepared from control cells stimulated only
with EGF. Negative controls included buffer-only controls and cell lysates prepared from
control cells after serum starvation.
6

Immunofluorescence Staining and Microscopy
Swiss 3T3 cells were grown on coverslips in DMEM plus 10% fetal calf serum (FCS; Gibco)
at 37°C in 5% CO2. Subconfluent cells were starved for 7.5 hrs in DMEM with 0.1% serum
then 0% serum for 2 or 3.5 hrs. Cells were treated with inhibitor for 1 h before stimulation.
As a positive control, cells were stimulated with 100 ng/ml bradykinin for 10 to 30 min
(Kozma, 1995).
Cells were washed with phosphate buffered saline, fixed with 4%
paraformaldehyde, permeabilized for 5 min with 0.1% Triton X-100 in Tyrode’s buffer,
blocked for 1 h with 1% BSA in Tyrode’s buffer. Cells were stained with Rhodamine
Phalloidin for filamentous actin (red) and Hoechst nuclear stain (blue) and then mounted in
Prolong Gold. A Zeiss LSM510 META and 63x 1.4NA objective was used to acquire the
images. The number of filopodia on each cell was counted.
iii) Center Summary of Results
Table 2. Assessment of CID2950007 in Key Biological Assays (based on CPDP Flow
Chart).
Assay Type

Target or System

Effect

Secondary

Nucleotide-depleted Cdc42 wild type, 1
mM MgCl2 and 1.5 nM BODIPY-FL-GTP
Cdc42 wild type with 1 mM EDTA and 100
nM BODIPY-FL-GTP
Cdc42 activated mutant with 1 mM EDTA
and 100 nM BODIPY-FL-GTP
Ras wild type with 1 mM EDTA and 100
nM BODIPY-FL-GTP
Ras activated mutant with 1 mM EDTA
and 100 nM BODIPY-FL-GTP
Rab 7 with 1 mM EDTA and 100 nM
BODIPY-FL-GTP
Rab 2a with 1 mM EDTA and 100 nM
BODIPY-FL-GTP
Rac1 wild type with 1 mM EDTA and 100
nM BODIPY-FL-GTP
Rac1 activated mutant with 1 mM EDTA
and 100 nM GTP
Cdc42 wild type with 1 mM MgCl2 and
100 nM GTP
Cdc42 activated mutant with 1 mM MgCl2
and 100 nM GTP
Rac1 wild type, Rac1 activated mutant,
Rho wild type, Rho activated mutant with
1 mM MgCl2 and 100 nM GTP
Cdc42 wild type, 10 µM 2950007, 1 mM
EDTA and 3 to 100 nM BODIPY-FL-GTP
Cdc42 wild type, 10 µM 2950007, 1 mM
MgCl2 and 3 to 100 nM BODIPY-FL-GTP
Nucleotide-depleted Cdc42 wild type, 10
µM 2950007, 1 mM MgCl2 and 3 to 1000
nM BODIPY-FL-GTP
Cdc42 binding to PAK-PBD beads in the
presence of 100 to 1000 nM GTPγS
Cdc42 GLISA in EGF-stimulated 3T3 cells
with 10 µM 2950007
Rac1 GLISA in EGF-stimulated 3T3 cells
with 10 µM 2950007
Bradykinin-stimulated filopodia formation
in 3T3 cells with 10 µM 2950007

IC50 = 0.2 µM

Primary
Primary
Primary
Primary
Primary
Primary
Primary
Primary
Secondary
Secondary
Secondary
Secondary
Secondary
Secondary
Secondary
Secondary
Secondary
Secondary
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IC50 = 2.6 µM
Range: 0.9-6.8
IC50 = 5.4 µM
Range: 2.1-13.1
IC50 = > 100 µM
IC50 = > 100 µM
IC50 = > 100 µM
IC50 = > 100 µM
IC50 = > 100 µM
IC50 = > 100 µM
IC50 = 4 µM
IC50 = 4 µM
All IC50 > 100 µM
> 50%
minimal
~ 50%
minimal
> 50%
minimal

decrease in Bmax,
effect on Kd for GTP
decrease in Bmax,
effect on Kd for GTP
decrease in Bmax,
effect on Kd for GTP

60 to 90% inhibition at 10
µM 2950007
> 50% inhibition
< 50% inhibition
> 50% inhibition

Primary HTS Assay: Dose Response Data
Binding of 8 different GTPases to 100 nM BODIPY FL-GTP was measured in multiplex format
in the presence of 1 mM EDTA in NP-HPS buffer. A GST-GFP control was used to eliminate
the possibility of compound effects on GST-protein binding to beads (data not shown). Dose
response analysis confirmed that CID2950007 (MLS 00693334) selectively inhibits only
Cdc42 binding to BODIPY FL-GTP with IC50 ~2 x10 -6 M (Figure 1a). CID2950007 did not
affect BODIPY-FL-GTP binding to Rac1, Rab2, Rab7 or Ras, either wild type or activated
mutant proteins, in the concentration range tested i.e. up to 100 µM. Equilibrium binding
studies confirmed that BODIPY-FL-GTP affinity for Cdc42 in the presence of 1 mM MgCl2 was
significantly enhanced to Kd ~ 0.5-1.5 nM as compared to Kd ~36-40 nM in the presence of
mM EDTA (data not shown). Accordingly for inhibition studies with GTPases in the presence
of 1 mM Mg2+ ions BODIPY-FL-GTP concentration was decreased to 1 nM. Figure 1b shows
a 6-plex assay with wild-type and constitutively active mutants of Rac1, RhoA, and Cdc42 in
the presence of Mg2+ ions. CID2950007 was a selective inhibitor for Cdc42 wt and Cdc42
(Q61L) binding to 1 nM BODIPY-FL-GTP in the presence of Mg2+ ions with IC50 ~4 µM.
CID2950007 did not significantly inhibit BODIPY-FL-GTP binding (< 10%) to RhoA or Rac1
up to 100 µM. In summary, using flow cytometry-based multiplex, high throughput
screening of BODIPY-FL-GTP binding to Rho family GTPases we identified CID2950007 as a
potent Cdc42 inhibitor (IC50 = 2 to 4 µM) with an excellent selectivity profile with respect to
all other related GTPase family we examined (selectivity ratio= 25 to 50).

Figure 1. Dose Response for CID2950007 against GTPase family members
The figure shows the inhibition profile of CID2950007/MLS000693334 against 8 GTPases in
the presence of 1 mM EDTA and 100 nM BODIPY-FL-GTP (Panel A) and 6 GTPases in the
presence of 1 mM Mg2+ and 1 nM BODIPY-FL-GTP (Panel B).
Secondary Assays: Mechanism of Action Studies
To confirm the biochemical mechanism of action of CID2950007 for Cdc42 GTPase
inhibition, BODIPY-FL-GTP equilibrium binding to wild-type Cdc42 was tested in the
presence or absence of CID2950007. Assays were performed with a fixed CID 2950007
concentration of 10 µM and monitoring BODIPY-FL-GTP binding over the range of 3 to 100
nM in the presence of 1 mM EDTA. CID2950007 decreased the Bmax of GTP-binding, while
BODIPY-FL-GTP affinity to wild type Cdc42 at Kd ~4 nM was essentially unchanged by
CID2950007 with Kd ~50 nM (Figure 2A). Very similar results were obtained for equilibrium
BODIPY-FL-GTP binding to Cdc42 in the presence of 1 mM MgCl2 (Figure 2B). Equilibrium
BODIPY-FL-GTP binding was also performed with wild type Cdc42 depleted of endogenous
bound nucleotide (GTP or GDP) by standard methods (Zhang, 2005) and in the presence of
1 mM Mg2+ with the BODIPY-FL-GTP concentration range extended out to 1 µM to ensure
full saturation, as evidenced by both linear and log plots (Figure 2C). These results
confirmed definitively the effect of CID 2950007 on Bmax rather than ligand affinity,
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establishing the mode of action as a potent and selective non-competitive Cdc42 inhibitor.
The nucleotide-depleted Cdc42 preparation was also tested in the presence of 1.5 nM
BODIPY-FL-GTP, 1 mM Mg2+ and varying inhibitor concentration (100 nM to 10 µM) to
establish an IC50 for CID2950007 of 200 nM and for CID2971684 of 400 nM (Figure 2D). A
10-fold lower IC50 for CID2950007 on nucleotide-depleted versus partially GTP/GDP bound
Cdc42 implies an allosteric/conformational interplay between GTP binding to the active site
of Cdc42 and the affinity/occupancy of the newly identified CID2950007 binding site.

6000

MCF

4000

2000

0
-10

-9

-8

-7

-6

-5

[compound] (log M)

Figure 2. CID2950007 is a Non-Competitive Inhibitor of Cdc42
Equilibrium binding studies were performed with 3-100 nM BODIPY-FL-GTP and wild type
Cdc42 plus 10 µM CID 2950007 (triangles) or DMSO vehicle (squares) with either (A) 1 mM
EDTA or (B) 1 mM Mg2+ ions. In (C) BODIPY-FL-GTP was tested from 10 nM to 1 µM in the
presence of Mg2+ ions using 10 µM CID2950007 and nucleotide-depleted Cdc42. The
principal mode of action is a decrease in GTP binding sites (Bmax) rather than a change in
GTP affinity. In (D), IC50 for CID 2950007 (squares) of 200 nM was determined using
nucleotide-depleted Cdc42, 1 mM Mg2+ ions and 1.5 nM BODIPY-FL-GTP. A related analog
CID 2971684 had IC50 = 400 nM (triangles) in this assay.
9

Secondary Biochemical Assay – GTPγS bound Cdc42:PAK-PBD Complex Formation
Since CID2950007 inhibits total GTP binding to Cdc42 we tested whether it could prevent
association of GTPγS-bound Cdc42 with PAK-PBD-GST beads using a pull down strategy and
Western blot for Cdc42. As shown in lanes 1 to 3 of Figure 3, in the presence of DMSO
robust association and pull down of active Cdc42 was achieved in the presence of 100, 500
and 1000 nM GTPγS. As shown in lanes 4 to 6, incubation with 10 µM CID2950007 almost
completely blocked the association of Cdc42 with PAK-PBD promoted by 100 and 500 nM
GTPγS (> 90% by densitometry) and was partially effective (>50% inhibition) in the
presence of 1000 nM GTPγS. These results are consistent with the equilibrium binding
studies showing that CID2950007 inhibits GTP binding to Cdc42.

Figure 3. CID2950007 Inhibits Cdc42 association with PAK-PBD. 40 nM His-Cdc42 wt
was incubated for 20 min at 30C with various concentrations of GTPγS in the presence of 1
mM EDTA and DMSO alone (lanes 1-3) or 10 µM CID2950007 (lanes 4-6). Reactions were
stopped by adding excess Mg2+. The mixture was incubated with 15 µl PAK-PBD beads
(Cytoskeleton, Inc.) for 1 h, washed 2 times and active Cdc42 was analyzed by Western blot
probing with a mAb directed against Cdc42. Lanes 1 and 4: 100 nM GTPγS; lanes 2 and 5:
500 nM GTPγS; lanes 3 and 6: 1000 nM GTPγS. Lane 7 is a specificity control incubation
containing PAK-PBD beads but no added Cdc42.
Secondary Cell-Based Assays
Having established the potency, selectivity and mechanism of action of CID2950007 as a
Cdc42 inhibitor, the activity profile of this innovative probe was tested using appropriate
secondary cell-based assays in the flow chart.
GLISA assays for CTP-Cdc42 and GTP-Rac Content in EGF-stimulated 3T3 cells
Figure 4 shows the results for Cdc42 (left panel) and Rac1 (right panel) G-LISA assays
obtained with Swiss 3T3 fibroblasts pre-incubated for 1 hour with 1 or 10 µM CID
2950007/MLS0000693334 and then stimulated for 2 min with 10 ng/ml epidermal growth
factor (EGF). Comparative data for 5 additional synthetic analogs of CID2950007 that were
developed during SAR analysis for probe optimization are also shown. Data are normalized
to the amount of GTP-bound Cdc42 or Rac-1 in the presence of EGF. There was a modest,
but reproducibly measurable increase (~40-50%) in GTP-Cdc42 content of 3T3 cells
following EGF stimulation consistent with published reports. The EGF-stimulated increase in
GTP-Cdc42 was inhibited in the presence of 10 but not 1 µM CID2950007. This suggests
robust intracellular inhibition of Cdc42 GTP-binding and activation by the probe. The close
analogs CID13927310/SID85148307 and CID44143700/SID85148308 had a similar profile
to CID2950007 in the G-LISA, whereas analogs CID44143703/SID85148312,
CID44143698/SID85148304 and CID13927312/SID85189505 either had no reproducible
effect or appeared to cause a counterintuitive increase in GTP-Cdc42 content. Assay for
GTP-Rac1 content by G-LISA showed a more robust signal to noise ratio of ~ 5:1 for EGF
stimulation versus baseline conditions (no EGF). Surprisingly, despite no evidence of any
Rac-1 GTPase inhibition up to 100 µM in the biochemical primary assays, there was a partial
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~ 30-50% inhibition of the EGF-stimulated increase in intracellular GTP-Rac-1 content in
cells pre-incubated with 1-10 µM CID2950007 and several related analogs. Although hard to
interpret, the results may imply off-target effects not related to direct Rac1 inhibition but
via intracellular targets regulating Rac1 activation status. Such a hypothesis could be
examined by broader MDS pharma testing against diverse receptor and kinase targets. The
analog CID44143700/SID85148308 had minimal effects in the Rac-1 assay at 1 or 10 µM.
Cdc42 GLISA
Rac GLISA Specificity Control
2.00

1.50
1.25

0.50

CID:13927312 1 µM

CID:13927312 10 µM

No EGF

Baseline
CID:44143703 1 µM

0.00
CID:44143703 10 µM

0.25

0.00

CID:44143700 1 µM

0.25

CID:44143700 10 µM

0.50

0.75

CID:13927310 1 µM

Baseline

CID:13927310 10 µM

0.75

+EGF

1.00

CID: 2950007 10 µM

+EGF

1.00

EGF

1.25

CID: 2950007 1 µM

ng GTP-Rac

1.50

No EGF
EGF
CID: 2950007 1 µM
CID: 2950007 10 µM
CID:13927310 1 µM
CID:13927310 10 µM
CID:441437001 µM
CID:44143700 10 µM
CID:44143703 1 µM
CID:4414370310 µM
CID:13927312
CID:13927312 10 µM
CID:44143698 1 µM
CID:44143698 10 µM

ng GTP-Cdc42

1.75

Figure 4. CID2950007 activity in cell-based GTP-Cdc42 and GTP-Rac1 content GLISA assays in 3T3 cells stimulated with EGF. 3T3 cells were serum starved in 6-well
dishes and incubated with inhibitors for 1 h then stimulated for 2 min with 10 ng/mL EGF.
Cells were washed with ice-cold phosphate buffered saline containing Ca2+ and Mg2 and
processed for G-LISA assay. Positive controls included GTP-Cdc42 or GTP-Rac1 provided in
the kit and lysates prepared from control cells stimulated only with EGF. Negative controls
included buffer-only controls and lysates prepared from control cells after serum starvation.
Bradykinin-induced filopodia formation
To further examine the probe in a cell based assay of activated Cdc42 function we examined
bradykinin-induced filopodia (peripheral actin microspikes, PAM) formation in 3T3 cells.
This cellular response was shown to be Cdc42-dependent in 3T3 cells (Kozma et al., 1995)
and recently to be ablated by Cdc42 gene silencing in mouse embryonic fibroblasts (Yang et
al., 2006). The results are shown in Figure 5. Panel A shows confocal images of a resting
3T3 cell with few filopodia, robust filopodia formation in a bradykinin-stimulated cell and
attenuation of this response by prior incubation with 10µMCID2950007. Table 3 and
Figure 5 Panel B shows the mean number of PAM/3T3 cell for cells treated with 0.1 %
DMSO vehicle alone (resting), resting + 10 µM CID2950007 without bradykinin, bradykinin
stimulation for either 10 or 15 min and bradykinin stimulation with pre-incubation of cells
for 60 min with CID2950007. Data shown are for a minimum of 10 and up to 17 cells
analyzed per condition. A robust increase of mean PAM/cell induced by bradykinin versus
vehicle control at both 10 and 15 min (3-4-fold) was strongly attenuated in cells pre-treated
with CID2950007
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Table 3. CID 2950007 Inhibits Filopodia Formation in 3T3 Fibroblasts
# Filopodia / cell
(mean +/- s.e.m.)
5.1 +/- 3.1
2.9 +/- 3.7
17.8 +/- 4.0
22.9 +/- 6.1
8.6 +/- 3.2
2.5 +/- 1.5

Resting 3T3 cells
Resting + 10 M CID2950007
200 ng/ml bradykinin, 10 min
200 ng/ml bradykinin, 10 min
10 M CID2950007 + bradykinin, 10 min
10 M CID2950007 + bradykinin, 15 min

A

B
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# cells evaluated
10
11
17
10
10
13

Figure 5. CID 2950007 inhibits bradykinin-induced filopodia formation.
Panel A shows confocal images with a few peripheral actin myospikes (PAM i.e. filopodia –
marked by arrows) on a resting Swiss 3T3 cell, a robust increase in PAM on a cell treated
with 200 ng/ml bradykinin and decreased PAM in a cell pre-treated with 10 µM CID2950007.
Panel B shows the mean number of PAM counted on a minimum of at least 10 individual 3T3
cells either resting (with 0.1% DMSO), resting for 60 min with 10 µM CID2950007, treated
for 10 or 15 min with 200 ng/ml bradykinin or 60 min with CID2950007 followed by
bradykinin. Data are the mean +/- s.e.m. for a minimum of 10 and up to 17 individual cells
analyzed.
PubChem Assays and General Selectivity Profile
A general pharmacological screen for the specificity/selectivity of CID 2950007 / MLS
0000693334 at physiologically relevant targets will be performed at MDS Pharma for
publication purposes. A ‘Bioactivity Analysis’ search in PubChem revealed that CID 2950007
/ MLS 0000693334 has been tested in 263 assays and is active in just 8 of these, of which 4
are bead-based GTPase assays described in this probe report (AID 761, 1333, 1334 and
1337). The remaining 4 assay “hits” are shown below:
Yeast-based HTS Assays
a) AID 868: “A screen for inhibitors of the budding yeast RAM network.”
The compound is described as a confirmed active but no IC50 is given. The RAM pathway in
budding yeast controls polarized growth, cell proliferation and gene expression. Of interest
both the RAM1 and RAM2 gene products in yeast regulate prenylation of GTPase pathways
(He, 1991).
b) AID 1362: “Screening for compounds that inhibit mitochondrial fusion using a yeast
model system as a primary screening tool”.
The compound is described as a confirmed active but no IC50 is given. Interestingly it is
stated in the assay description that “we have identified proteins that are required for
mitochondrial fission and fusion...the key proteins among these are three dynamin-related
proteins (DRPs), which are large self-assembling GTPases”.
Given the conserved cellular functions of small GTPases across phyla and the 80% sequence
identity between human and S. cerevisiae Cdc42 a hit in the above GTPase-dependent
primary assay systems would not be unexpected.
Mammalian Cell Based Assays
AID 1885 and AID 2044: “HTS to Identify Inhibitors of T. Cruzi Replication.”
This is a 90-hour assay for parasite replication in 3T3 cells, nota bene the same cell line we
have used for filipodia experiments. CID 2950007 / MLS 0000693334 is described as active
in the primary T. cruzi replication HTS and to have IC50 = 2.8 µM in a confirmed dose
response. This cellular potency is in the range we have noted for the G-LISA and filipodia
assays in 3T3 cells (IC50 <10 µM). Rho GTPases, including Cdc42, are implicated in T. cruzi
invasion in MDCK cells (Dutra 2005) and Cdc42 is involved in the invasion / replication /
infection processes for viruses (Van den Broek, 2010) and other pathogens, such as
pneumococci (Agarwal V. 2009).
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In conclusion, CID 2950007 / MLS 0000693334 is highly selective Cdc42 chemical probe
within the rho GTPase family we have tested and appears to have broad pharmacological
specificity based on assay data compiled in the MLPCN databases.
Probe Optimization
The primary HTS screen identified CID 2950007/MLS000693334 as a promising hit
compound (Figure 6). The compound showed inhibitory potency and selectivity for Cdc42
WT and Cdc42 ACT and was devoid of any significant activity for the other GTPases
surveyed.

OMe

N N
SO2 NH2

CID 2950007
MLS000693334

Figure 6. Hit scaffold and dose response curves illustrating selectivity for Cdc42
Over the course of the SAR expansion and testing, this substance was assayed on six
occasions. The substance was first sourced from BioFocus DPI as part of the cherry pick
selection in the HTS phase. The compound was then ordered from commercial sources
(ChemBridge) as part of a solid retest, and finally, the compound was prepared at the KU
SCC and submitted for repeated assay comparison as new analogs were generated for the
primary assay. An average of the tabulated potency and efficacy was used as the
benchmark against which analogs were compared. The data for the compiled survey of this
substance is presented in Table 4.
Table 4. Summary of data from primary assay collected on hit compound
CID 2950007/MLS000693334

Source

Identifier

DPI
MLS000693334
Chembridge
SID57644019
Chembridge
SID 57644019
KU SCC
SID 57578341
KU SCC
SID 57644019
KU SCC
SID 57578387
Average Value

Cdc42
ACT EC50
µM

Cdc42
ACT
Efficacy

Cdc42
WT EC50
µM

Cdc42
WT
Efficacy

8.0
2.1
2.1
3.4
3.5
13.1
5.4

70%
54%
59%
57%
53%
46%
57%

3.2
1.2
1.2
0.85
2.2
6.7
2.6

82%
78%
81%
51%
71%
50%
69%

Averaged data collected in the primary dose response assay for the hit scaffold satisfied the
criteria set for passing into secondary assays. As such, this compound was further
evaluated while SAR was initiated on the series.
Compounds of the same chemotype in the HTS screen lacked significant inhibitory activity
and/or efficacy for Cdc42. An SAR strategy was devised that independently targeted the
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four rings of the structure. This effort was done with the aim of preserving the selectivity
and improving potency for Cdc42 as determined by the primary dose response assay,
enhancing efficacy of 65% or better in the primary assay for Cdc42 WT, and demonstrating
suitable activity in secondary assays.
The parent structure was dissected into four regions for medicinal chemistry and SAR
follow-up (Figure 7). Modifications and their impact are discussed in detail below.

Structural SAR Summary
Multiple Changes
(42 examples)

OMe

4-Methoxyphenyl Ring
4(19 examples)

Phenyl Ring
(27 examples)

N N
SO2NH2

Central Ring

Phenyl Sulfonamide Ring
(6 examples)

(1 example)

Aromatization
Figure 7. Overview of structural variations resulting from SAR efforts
Modification of the N-phenyl-4-sulfonamide moiety: Bioisosteric replacement of the
sulfonamide functional group produced compounds devoid of any significant inhibitory
GTPase activity. Exchange of the phenylsulfonamide for a phenyl ring substituted in the 4position with a sulphone (4-SO2CHF2), carboxylic acid (4-CO2H), amide (4-CO2NH2), or nitro
OMe (4-NO2) group resulted in complete loss of inhibitory activity.
Removal of the sulfonamide or substitution with alkyl or alkoxy
groups or halides, in combination with other changes on the
structure, also dramatically attenuated the potency or efficacy
(i.e., flat dose response curves) as compared to the hit
N
N
R1
compound. Migration of the sulfonamide group to alternate 2or 3- positions on the phenyl ring produced analogs with inferior potency and efficacy
profiles. As such, this key functionality was quickly assessed as a critical component of the
scaffold that would be held constant as other structural features were surveyed.
Representative PubChem CIDs for these changes are 2865225, 5181298, 2952426,
44216863, and 44246341.
Modification of the phenyl moiety: Systematic, single point changes on this appendage
of the parent scaffold resulted in 27 analogs. Substitutions made in concert with other
structural alterations afforded an additional 27 analogs.
OMe
Modifications focused on a survey of the electronic and spatial
requirements for this region of the scaffold. The addition of
substituents in any of the available positions on the phenyl
R2
ring generally produced analogs with decreased efficacy
N N
compared to the parent, thus generating very shallow and
broad dose response curves. A few exceptions were found.
SO 2NH2
Installation of a 2-methoxy group on the phenyl ring produced
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a compound with CID 44143702 which showed similar potency to the hit compound with
Cdc42 ACT/WT activity of 5.5 µM (42% efficacy) and 6.0 µM (59% efficacy), respectively.
Replacement of the phenyl group with a 2-thiophene group gave compound CID44143712
with results similar, but not superior to, those observed with the parent hit (Table 5). The
use of a 3-thiophene group resulted in a loss of potency and efficacy compared to the hit
compound. Incorporation of alkyl groups in place of an aryl moiety was not beneficial.
Table 5. Selected examples of SAR from modifying the phenyl moiety (R2) of the
MLS000693334 scaffold

Entry

R2

PubChem
CID

Cdc42
ACT EC50
µM

Cdc42
ACT
Efficacy

Cdc42
WT EC50
µM

Cdc42 WT
Efficacy

1
2
3
4
5
6
7

2-OMe-phenyl
3-OMe-phenyl
4-OMe-phenyl
2-thiophene
3-thiophene
methyl
tert-butyl

44143702
44143698
15201811
44143712
44143713
14870296
44193701

5.5
1.6
2.5
4
7.3
> 100
> 100

42%
30%
23%
42%
33%
16%
29%

6
1.5
2.6
2.9
7.3
> 100
> 100

59%
50%
38%
57%
47%
17%
33%

Modification of the 4-methoxyphenyl moiety: Systematic, single-point substitution of
this particular phenyl ring (R3) afforded 19 compounds with various electronically activating
or deactivating groups. Changes made on this ring in
R3
combination with other structural modifications afforded an
additional 39 analogs. Variations in this region yielded
N N
several compounds with a comparable or improved profile
as compared to the parent hit in the primary dose response
SO2NH2 assay. Results of this effort are summarized in Table 6.
Table 6. Selected examples of SAR from modifying the 4-methoxyphenyl moiety
(R3) of the MLS000693334 scaffold

Entry

R3

PubChem
CID

Cdc42
ACT EC50
µM

Cdc42 ACT
Efficacy

Cdc42
WT EC50
µM

Cdc42
WT
Efficacy

1
2
3
4
5
6
7
8
9
10
11
12
13
14

phenyl
2-Br-phenyl
3-Br-phenyl
4-Br-phenyl
2-Cl-phenyl
3-Cl-phenyl
4-Cl-phenyl
3-F-phenyl
2-MeO-phenyl
3-MeO-phenyl
2-Me-phenyl
3-Me-phenyl
4-Me-phenyl
3,4-diMeO-phenyl

2837695
44216862
44143703
13927312
44193697
44193696
13927311
12005853
42628035
44143701
44143704
44143700
13927310
2971684

16.8
> 100
3.7
1.7
7.4
3.6
3.6
9.6
78.9
4.3
13.6
5.3
5.0
6.1

44%
NA
50%
52%
27%
51%
56%
58%
34%
39%
42%
50%
46%
56%

31.6
> 100
3.3
1.1
7.2
3.3
2.8
4.9
22.5
4.8
16.6
5.0
5.0
5.7

56%
NA
55%
56%
39%
64%
69%
71%
45%
53%
55%
55%
66%
75%
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Substitutions at the 2-position of this phenyl ring resulted in deteriorated potency as
compared to those same substitutions at the 3- or 4-position of the same ring (entries 2, 5,
9, and 11 in Table 6). Shaded entries represent analogs with sufficiently interesting
potency and efficacy profiles that they were considered for secondary assay assessment.
OMe

N N
SO2 NH2

CID 14199398

Modification of the central dihydropyrazoline core: This
scaffold exists in a puckered conformation as a result of the
dihydropyrazoline ring. Compounds possessing an aromatic
pyrazoline ring with similar aromatic appendages have been
the subject of clinical significance (Penning, 1997). In order to
assess the effect of flattening out the scaffold in the context
of GTPase activity, the analog featuring an oxidized central
ring was prepared. The efficacy was sub-optimal, resulting in
almost a flat dose response curve.

Tandem structural modifications (changes in more than one region at a time):
Many of the compounds in this category were screened as a part of a commercially available
set and did not possess structural elements that we later discovered to be critical to
effective inhibition of Cdc42. In most cases, these compounds lead to flat dose response
curves or activation instead of the desired inhibitory activity. However, a few compounds
were deliberately prepared as a means to incorporate structural features that were
beneficial in previous SAR rounds as described above. One example was CID 44216842,
featuring a combination of the best of what was learned from single point changes made
during the course of SAR exploration (Figure 8). Knowing that a boost in potency was
observed with these substituents, the 4-bromophenyl (R3) and 3-methoxyphenyl (R2) aryl
groups were incorporated into the same analog. The result was a sub-micromolar potent,
Cdc42 ACT/WT selective GTPase inhibitor, devoid of Rac activity. The efficacy of this analog
was almost equivalent to that of the parent observed for Cdc42 ACT and ca. 10% less than
that of the parent for Cdc42 WT.

PubChem
CID

Cdc42
ACT EC50
µM

Cdc42
ACT
Efficacy

Cdc42 WT
EC50 µM

Cdc42
WT
Efficacy

44216842

0.66

55%

0.40

57%

CID 44216842

Figure 8. Primary dose response assay data for CID 44216842
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The throughput of the secondary GLISA assay was low (AID 2375). As such, a handful of
compounds were analyzed. Compounds selected for evaluation included those structures
shown in Figure 9.

Figure 9. Selected compounds for GLISA analysis (AID 2375)
The results of the GLISA assay determined that the parent compound (MLS000693334, CID
2950007), and compounds with CIDs 44143700 and 13927310 showed a significant
response at 10 µM to inhibit Cdc42 with similar potency and efficacy to each other
3. Probe Information and Characteristics
a. CHEMICAL IUPAC NAME:
4-[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide [ML141]
b. STRUCTURE AND STEREOCHEMISTRY: (Racemic)
OMe
H
N

N
SO2 NH 2

c. STRUCTURAL VERIFICATION INFORMATION OF PROBE MLS000693334 (CID:
2950007):
See Section h. Synthetic Route and Characterization below.
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d. PUBCHEM SID AND CID OF PROBE:
Probe
Probe
Probe
Probe

PubChem
PubChem
PubChem
NEW MLS

CID: 2950007
Original SID (Chembridge): 57644019
NEW SID: 57578341
Number: MLS002699035

e. SUPPLIERS, VENDORS AND CONTACT INFORMATION:
VENDOR
LIST DATE

ChemBridge Screening Library
January 2010 (SciFinder)

ORDER NUMBER

7725949

CHEMICAL NAME AS
USED BY VENDOR

4-[5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1Hpyrazol-1-yl]benzenesulfonamide

REGISTRY NUMBER

71203-35-5

PRICING

1 mg / $40

COMPANY INFO

ChemBridge Corporation
16981 Via Tazon, Suite G
San Diego, CA, 92127
USA
Phone: (800) 964-6143
Phone: (858) 451-7400
Fax: (858) 451-7401
Web: http://www.chembridge.com

This compound is also available from the University of Kansas, Specialized Chemistry
Center. If you are interested in the probe compound, itemized analogs or other
derivatives of this scaffold, please contact our Compound Curator and reference the
PubChem SID, if available:
Mr. Patrick Porubsky
KU SCC Compound Curator
Structural Biology Center
Lawrence, KS 66047
pporubsky@ku.edu
(785) 864-6167
f. MLS NUMBER UPON SUBMISSION TO THE MLSMR:
Date:

February 22, 2010

New MLS Assignments of Probe
MLS002699035 CID: 2950007

Original SID: 57578341

New MLS Assignments of Related Analogs:
MLS002699036

CID: 44143698

Original SID: 85148304

MLS002699037

CID: 44143703

Original SID: 85148312
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MLS002699038

CID: 13927312

Original SID: 85189505

MLS002699039

CID: 44143700

Original SID: 85148308

MLS002699040

CID: 13927310

Original SID: 85148307

g. MODE OF ACTION
The probe is a potent, selective and reversible non-competitive inhibitor of Cdc42
GTPase as determined by a bead-based Cdc42/GTP substrate assay. The inhibitor
potency is ~ 2 µM in the presence of EDTA and 100 nM BODIPY-FL-GTP and ~ 200 nM in
the presence of 1 mM Mg2+ ions and 1 nM BODIPY-FL-GTP. No appreciable inhibitory
activity up to 100 µM was observed with Rac1, Rab2, Rab7 or Ras. This Cdc42-specific
probe has low micromolar activity (1-10) in qualitative and semi-quantitative cell-based
assays of such as GLISA assay for active GTP-bound Cdc412/PAK-PBD complex and
Cdc42-dependent function in filopodia formation in 3T3 cells. The probe has not been
extensively characterized for general pharmacological selectivity against physiologically
relevant targets and its in vivo profile is not known.
h. SYNTHETIC ROUTE:

Figure 10. General synthetic scheme for the synthesis of dihydropyrazolines
General experimental and analytical details: 1H and 13C NMR spectra were recorded
on a Bruker AM 400 spectrometer (operating at 400 and 101 MHz respectively) in CDCl3
with 0.03% TMS as an internal standard or DMSO-d6. The chemical shifts ( reported are
given in parts per million (ppm) and the coupling constants (J) are in Hertz (Hz). The
spin multiplicities are reported as s = singlet, br. s = broad singlet, d = doublet, t =
triplet, q = quartet, dd = doublet of doublet and m = multiplet. The LCMS analysis was
performed on an Agilent 1200 RRL chromatograph with photodiode array UV detection
and an Agilent 6224 TOF mass spectrometer. The chromatographic method utilized the
following parameters: a Waters Acquity BEH C-18 2.1 x 50mm, 1.7µMcolumn; UV
detection wavelength = 214nm; flow rate = 0.4ml/min; gradient = 5 - 100% acetonitrile
over 3 minutes with a hold of 0.8 minutes at 100% acetonitrile; the aqueous mobile
phase contained 0.15% ammonium hydroxide (v/v). The mass spectrometer utilized the
following parameters: an Agilent multimode source which simultaneously aquires
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ESI+/APCI+; a reference mass solution consisting of purine and hexakis(1H, 1H, 3Htetrafluoropropoxy)phosphazine;
and
a
make-up
solvent
of
90:10:0.1
MeOH:Water:Formic Acid which was introduced to the LC flow prior to the source to
assist ionization. The melting point was determined on an Electrothermal Mel-Temp
melting point apparatus.
Chalcone synthesis (STEP 1): For analogs of CID: 2950007/ MLS000693334,
chalcones were synthesized as shown in step 1 of Figure 10. The general procedure is
described as follows: To a stirred solution of NaOH (1.2 eq, 6.25 mmol, 0.25 g) in H2O
(2.5 mL) was added the ketone (1eq, 5.0 mmol) in EtOH (1.5 mL). The solution was
cooled to 0°C and then the aldehyde (1eq, 5.0 mmol) was gradually added. Once the
addition was complete, the mixture was allowed to warm to room temperature and was
stirred for 12 – 36 hours, until judged complete by LCMS. The reaction was quenched
by the addition of NH4Cl sat. solution (4 mL) and extracted with EtOAc (2 x 8 mL). The
Filtration and
organic layer was separated, combined, and dried over Na2SO4.
concentration of the solvent in vacuo afforded the desired product in sufficient purity for
further use (Isleyen, 2007).

OMe
H
N

N
SO2 NH 2

Probe: MLS000693334; CID: 2950007
4-[3-(4-methoxyphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzenesulfonamide:
For the synthesis of this compound, the requisite chalcone starting material was
commercially available. 4-Methoxychalcone (3, R1 = H, R2 = 4-OMe, CAS# 959-33-1) was
purchased from Sigma-Aldrich and 4-hydrazinobenzene-1-sulfonamide hydrochloride (4,
CAS# 17852-52-7) was purchased from Acros Organics. (STEP 2): To a 20 mL microwave
vial was added 4-methoxychalcone (0.238 g, 1.00 mmol, 1 eq), EtOH (200 proof, 10 mL),
4-hydrazinobenzene-1-sulfonamide hydrochloride (0.252 g, 1.13 mmol, 1.1 eq), and glacial
AcOH (0.29 mL, 5.0 mmol, 5 eq). The vessel was sealed and then submitted to microwave
irradiation at 150 C for 1 h. Once the reaction mixture had cooled to room temperature,
the cap was removed and the vessel was placed in a dry-ice/acetone bath. While stirring,
hexane (10 mL) was added, and the resulting precipitate was collected by filtration. The
precipitate was rinsed with hexane (3  10 mL) and then the solid was transferred to
another flask and recrystallized from EtOH (6 mL). The solid was filtered, rinsed with
hexanes (3  10 mL) and dried to afford 4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1Hpyrazol-1-yl)benzenesulfonamide (0.150 g, 37% yield, 97% purity by LCMS at 254 nm) as
white needles. 1H NMR (400 MHz, DMSO-d6) δ 7.80 (m, 2H), 7.58 (d, J = 9.0 Hz, 2H), 7.43
(m, 3H), 7.18 (d, J = 8.7 Hz, 2H), 7.09 (d, J = 9.0 Hz, 2H), 7.02 (s, 2H), 6.90 (d, J = 8.7
Hz, 2H), 5.60 (dd, J = 12.0, 5.1 Hz, 1H), 3.95 (dd, J = 17.6, 12.0 Hz, 1H), 3.71 (s, 3H),
3.17 (dd, J = 17.7, 5.1 Hz, 1H). 13C NMR (101 MHz, DMSO-d6) δ 158.59, 149.58, 145.87,
133.48, 132.98, 131.83, 129.24, 128.69 (x 2), 127.06 (x 2), 126.99 (x 2), 126.02 (x 2),
114.42 (x 2), 112.02 (x 2), 61.88, 55.02, 42.97. Compounds of this chemotype submitted
to LCMS analysis routinely showed a parent mass and/or a parent mass - 2, the latter of
which resulted presumably due to an analytical instrument artifact that resulted in
oxidation/aromatization of the central dihydropyrazoline ring on the LCMS column, in the
MS detector, or both. In this case, both ions were observed in the same peak. LCMS
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retention time: 3.057 min. HRMS m/z calculated for C22H21N3NaO3S [M++Na]: 430.1196,
found 430.1180. For aromatized/oxidized signal, HRMS m/z calculated for C22H20N3O3S [M+2+1] 406.1225, found 406.1217. White needles, mp 185-187 °C. (Faid-Allah, 1988).

Analog: MLS002699036; CID: 44143698
4-[5-(3-methoxyphenyl)-3-(4-methoxyphenyl)-3,4-dihydropyrazol2-yl]benzenesulfonamide: This analog was prepared as depicted in steps 1 and 2 in
Figure 10. Isolated 176mg, 0.40 mmol, 96% yield, as a yellow solid. 1H NMR (400 MHz,
DMSO-d6)  7.58 (d, J = 9.0 Hz, 2H), 7.36 (m, 2H), 7.32 (d, J = 1.8 Hz, 1H), 7.17 (d, J =
8.8 Hz, 2H), 7.09 (d, J = 9.0 Hz, 2H), 7.02 (s, 2H), 6.98 (m, 1H), 6.90 (d, J = 8.8 Hz, 2H),
5.59 (dd, J = 12.0, 5.1 Hz, 1H), 3.92 (dd, J = 17.7, 12.1 Hz, 1H), 3.82 (s, 3H), 3.70 (s,
3H), 3.17 (dd, J = 17.7, 5.1 Hz, 1H). 13C NMR (101 MHz, DMSO-d6)  159.45, 158.61,
149.52, 145.83, 133.49, 133.21, 133.03, 129.83, 127.07 (x 2), 127.01 (x 2), 118.59,
115.23, 114.44 (x 2), 112.08 (x 2), 110.96, 61.90, 55.21, 55.05, 43.04. LCMS retention
time: 3.050 min. HRMS m/z calculated for C23H23N3NaO4S [M+ + Na]: 460.1301, found
460.1282. For aromatized/oxidized signal, HRMS m/z calculated for C23H22N3O4S [M+-2+1]
436.1326, found 436.1319.

Analog: MLS002699037; CID: 44143703
4-[3-(3-bromophenyl)-5-phenyl-3,4-dihydropyrazol-2-yl] benzene sulfonamide:
This analog was prepared as depicted in steps 1 and 2 in Figure 10. Isolated 132mg, 0.29
mmol, 69% yield as a yellow solid. 1H NMR (400 MHz, DMSO-d6)  7.79 (dd, J = 8.1 Hz, 1.5
Hz, 2H), 7.61 (d, J = 9.0 Hz, 2H), 7.52 – 7.39 (m, 5H), 7.31 (t, J = 7.8 Hz, 1H), 7.22 (d, J
= 7.8 Hz, 1H), 7.09 (d, J = 8.9 Hz, 2H), 7.04 (s, 2H), 5.68 (dd, J = 12.1, 5.1 Hz, 1H), 3.98
(dd, J = 17.8, 12.2 Hz, 1H), 3.25 (dd, J = 17.8, 5.1 Hz, 1H). 13C NMR (101 MHz, DMSO-d6)
 149.80, 145.68, 144.31, 133.34, 131.59, 131.39, 130.57, 129.41, 128.72 (x 2), 128.65,
127.23 (x 2), 126.15 (x 2), 124.71, 122.19, 112.01 (x 2), 61.65, 42.79. LCMS retention
time: 3.253 min.
Parent ion observed as a dimer: HRMS m/z calculated for
C42H34Br2N6NaO4S2 [2M+ + Na-2]: 933.0325, found 933.0358. For aromatized/oxidized
signal, HRMS m/z calculated for C21H17BrN3O2S [M+-2+1] 454.0219, found 454.0215.
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Analog: MLS002699038; CID: 13927312
4-[3-(4-bromophenyl)-5-phenyl-3,4-dihydropyrazol-2-yl]benzene
sulfonamide:
This analog was prepared as depicted in steps 1 and 2 in Figure 10. Isolated 137mg, 0.30
mmol, 71%) was observed as a white solid. 1H NMR (400 MHz, DMSO-d6)  7.79 (dd, J =
8.1, 1.5 Hz, 2H), 7.60 (d, J = 9.0 Hz, 2H), 7.54 (d, J = 8.5 Hz, 2H), 7.44 (m, 3H), 7.22 (d,
J = 8.5 Hz, 2H), 7.07 (d, J = 9.0 Hz, 2H), 7.03 (s, 2H), 5.66 (dd, J = 12.1, 5.0 Hz, 1H),
3.97 (dd, J = 17.7, 12.1 Hz, 1H), 3.21 (dd, J = 17.7, 5.1 Hz, 1H). 13C NMR (101 MHz,
DMSO-d6)  149.72, 145.69, 140.97, 133.25, 132.00 (x 2), 131.64, 129.38, 128.72 (x 2),
128.12 (x 2), 127.19 (x 2), 126.11 (x 2), 120.66, 112.02 (x 2), 61.69, 42.69. LCMS
retention time: 3.269 min. For aromatized/oxidized signal, HRMS m/z calculated for
C21H17BrN3O2S [M+-2+1] 454.0219, found 454.0221.

Analog: MLS002699039; CID: 44143700
4-[3-(3-methylphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl] benzene sulfonamide:
This analog was prepared as depicted in steps 1 and 2 in Figure 10. Isolated 90mg, 0.23
mmol, 55% yield as a yellow solid. 1H NMR (400 MHz, DMSO-d6)  7.79 (dd, J = 8.1, 1.5
Hz, 2H), 7.58 (d, J = 9.0 Hz, 2H), 7.44 (m, 3H), 7.22 (t, J = 7.6 Hz, 1H), 7.14 – 6.97 (m,
7H), 5.58 (dd, J = 12.1, 5.4 Hz, 1H), 3.97 (dd, J = 17.7, 12.2 Hz, 1H), 3.17 (dd, J = 17.7,
5.4 Hz, 1H), 2.26 (s, 3H). 13C NMR (101 MHz, DMSO-d6)  149.59, 145.93, 141.75, 138.36,
133.04, 131.76, 129.29, 128.99, 128.72 (x 2), 128.33, 127.13 (x 2), 126.17, 126.07 (x 2),
122.75, 111.93 (x 2), 62.40, 43.04, 21.09. LCMS retention time: 3.212 min.
For
aromatized/oxidized signal, HRMS m/z calculated for C22H20N3O2S [M+-2+1]: 390.1271,
found 390.1268.
SO2NH2

N N
Me

Analog: MLS002699040; CID: 13927310
4-[3-(4-methylphenyl)-5-phenyl-3,4-dihydropyrazol-2-yl] benzene sulfonamide:
This analog was prepared as depicted in steps 1 and 2 in Figure 10. Isolated 130mg, 0.33
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mmol, 79% yield as a yellow solid. 1H NMR (400 MHz, DMSO-d6)  7.79 (dd, J = 8.1, 1.5,
2H), 7.58 (d, J = 9.0 Hz, 2H), 7.43 (m, 3H), 7.14 (s, 4H), 7.07 (d, J = 8.9 Hz, 2H), 7.02 (s,
2H), 5.60 (dd, J = 12.1, 5.1 Hz, 1H), 3.95 (dd, J = 17.7, 12.1 Hz, 1H), 3.16 (dd, J = 17.7,
5.1 Hz, 1H), 2.24 (s, 3H). 13C NMR (101 MHz, DMSO-d6)  149.60, 145.86, 138.64, 136.81,
132.99, 131.80, 129.63 (x 2), 129.27, 128.71 (x 2), 127.09 (x 2), 126.04 (x 2), 125.68 (x
2), 112.00 (x 2), 62.14, 42.94, 20.62. LCMS retention time: 3.224 min.
For
aromatized/oxidized signal, HRMS m/z calculated for C22H20N3O2S [M+-2+1] 390.1271,
found 390.1266.
i. SUMMARY OF PROBE PROPERTIES: MLS002699035; CID: 2950007
Physical appearance and properties: The compound was isolated as white needles with
melting point range of 185-187 °C. The compound formed a mass when collected as
described above that resembled spun wool. The purity was determined to be 97% by LCMS
at 254 nm.
LCMS behavior: Upon analysis by LCMS, compounds of this type commonly showed a mass
consistent with aromatization/oxidation of the central dihydropyrazoline core, [M+-2+1].
This was determined to be an artifact of the LCMS method, as the ratio of parent ion [M+ +
1] to oxidized ion [M+-2+1] could be modulated to a limited degree by varying the method
parameters. Additionally, compounds that showed significant ratios of the two ions by
LCMS were clearly pure by 1H NMR and were not mixtures reflective of the observed LCMS
product ratio.
It is also notable that intentionally prepared oxidized analogs were compared to their
unoxidized dihydropyrazoline analogs by 1H NMR and by bioassay. The oxidized compounds
were easily recognized by diagnostic signals in the 1H NMR and did not possess GTPase
inhibitory activity.
1

H and 13C NMR in CDCl3: The probe compound NMR characterization was obtained in
DMSO-d6 and CDCl3. The DMSO data can be directly compared to the other analogs and is
represented in the experimental section. The CDCl3 data is offered here for convenience.
1

H NMR (400 MHz, CDCl3) δ 7.73 (m, 2H), 7.67 (d, J = 9.0 Hz, 2H), 7.39 (m, 3H), 7.15 (d, J
= 8.7 Hz, 2H), 7.07 (d, J = 8.9 Hz, 2H), 6.84 (d, J = 8.7 Hz, 2H), 5.31 (dd, J = 12.1, 5.8
Hz, 1H), 4.60 (s, 2H), 3.85 (dd, J = 17.3, 12.1 Hz, 1H), 3.76 (s, 3H), 3.18 (dd, J = 17.3,
5.8 Hz, 1H). 13C NMR (101 MHz, CDCl3) δ 159.55, 149.75, 147.59, 133.43, 132.24, 130.43,
129.66, 128.91 (x 2), 128.25 (x 2), 127.09 (x 2), 126.33 (x 2), 114.98 (x 2), 112.82 (x 2),
63.32, 55.53, 43.92.
Literature precedent of synthesis and melting point: The synthesis and melting point
of this compound has been described (Faid-Allah, 1988). The literature melting point was
reported as 216 °C which was higher than that which was experimentally determined in our
lab (mp 185-187 °C). We cannot account for the discrepancy, but we noted it.
j. TABULATED SUMMARY OF KNOWN PROBE PROPERTIES: See page 1

4. Comparison to Prior Art for Cdc42 Inhibitors
As stated in the CPDP for this project there was no prior art describing direct Cdc42
inhibitors, so the discoveries reported here are highly innovative and impactful. Shown
below is the structure of Secramine which is not a direct inhibitor of Cdc42. The compound
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was synthesized predicated on brefeldin A, which is a fungal metabolite. that stabilizes a
complex between Arf and Arf GEF thereby blocking GTPase activation (Pelish 2006).

Secramine
The stability, solubility and broad-spectrum target profiling of these compounds has yet to
be assessed. With respect to stability, deterioration of compound purity was not observed
over weeks during which time the compounds were handled. Spontaneous oxidation of the
central pyrazoline core was also not observed unless under the conditions of LCMS analysis.
Moreover, with respect to solubility and cross-target reactivity, this structural class of
compounds has been dosed orally and shown to inhibit COX-1 and COX-2 enzymes in a rat
carrageenan model of inflammation (Rathish, 2009). Modified versions of the structural
class, of which Celecoxib belongs, have been pursued clinically and shown to be
therapeutically useful oral agents.
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